Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Blood Cancer Journal|November 24, 2018
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyureaAnnalisa Pacilli, Giada Rotunno, Carmela Mannarelli, et al.
Haematologica|April 9, 2026
Changes in neutrophil-to-lymphocyte ratio in patients with polycythemia vera treated with ruxolitinib reflect <i>JAK2</i> variant allele frequencyPaola Guglielmelli, Chiara Paoli, Giulia Borgi, et al.
American Journal of Hematology|March 26, 2022
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosisFrancesco Mannelli, Sara Bencini, Giacomo Coltro, et al.
Clinical and Experimental Medicine|February 18, 2020
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literatureGiacomo Coltro, Francesco Mannelli, Federica Vergoni, et al.
Blood Cancer Journal|December 13, 2021
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosisPaola Guglielmelli, Giuseppe G Loscocco, Carmela Mannarelli, et al.
American Journal of Hematology|August 23, 2021
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patientsGiuseppe G Loscocco, Paola Guglielmelli, Naseema Gangat, et al.
Blood|January 25, 2014
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II studyPaola Guglielmelli, Flavia Biamonte, Giada Rotunno, et al.
Plos One|December 6, 2019
Eavesdropping on dolphins: Investigating the habits of bottlenose dolphins (Tursiops truncatus) through fixed acoustic stationsJessica Alessi, Alberta Mandich, Maurizio Wurtz, et al.
Blood|March 30, 2017
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosisPaola Guglielmelli, Annalisa Pacilli, Giada Rotunno, et al.
American Journal of Hematology|June 6, 2024
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemiaPaola Guglielmelli, Barbara Mora, Francesca Gesullo, et al.
Pageof 3